Analysts have been eager to weigh in on the Healthcare sector with new ratings on Acceleron Pharma (XLRN) and Pacira Pharmaceuticals (PCRX).
Acceleron Pharma (XLRN)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on Acceleron Pharma, with a price target of $67. The company’s shares opened today at $46.25.
“Our $67 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline and estimated year-end cash. We use the net present value of our revenue forecast through 2026, apply a 65% probability of success and a 2.5x price/sales multiple for luspatercept, and our year-end cash estimate to arrive at our price target. We use a 20% discount rate for the pipeline as it is above the marketed products discount rate due to development risks but within the typical range of 15-25% for products in development.”
According to TipRanks.com, White is a 5-star analyst with an average return of 13.7% and a 47.0% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
Acceleron Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $72.50, representing a 56.8% upside. In a report issued on February 27, Cowen & Co. also assigned a Buy rating to the stock with a $78 price target.
See today’s analyst top recommended stocks >>
Pacira Pharmaceuticals (PCRX)
Cowen & Co. analyst Boris Peaker maintained a Hold rating on Pacira Pharmaceuticals today. The company’s shares opened today at $39.95.
According to TipRanks.com, Peaker is a 4-star analyst with an average return of 5.7% and a 43.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.
Pacira Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $54, implying a 35.2% upside from current levels. In a report issued on March 1, BMO Capital also maintained a Hold rating on the stock with a $44 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.